OrienX 010

Drug Profile

OrienX 010

Alternative Names: OrienX010; Recombinant hGM-CSF Herpes Simplex Virus - OrienGene Biotechnology; Recombinant hGM-CSF HSV - OrienGene Biotechnology; rhGM-CSF Herpes Simplex Virus - OrienGene Biotechnology; rhGM-CSF HSV - OrienGene Biotechnology

Latest Information Update: 15 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OrienGene Biotechnology
  • Developer Beijing Bozhiyin T&S; OrienGene Biotechnology; START Shanghai
  • Class Cancer vaccines; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Cell membrane modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 Mar 2016 Phase-I development is ongoing in China
  • 01 May 2012 Phase-I clinical trials in Solid tumours in China (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top